Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

On 17 February 2018, a USD $2.54 billion verdict against Gilead infringement related with Merck Hep-C patents was overturned.

In the first instance judgment –occurred on December 2016-, a jury declared that Gilead infringed Merck patents over its Hepatitis C Drugs, and was charged $2.54 billion.  However, U.S. District Judge Leonard Stark has overturned the original verdict by confirming Merck’s patent that was allegedly infringed on, is actually invalid.